Europe - Euronext Milan - BIT:1TMO - US8835561023 - Common Stock
The current stock price of 1TMO.MI is 541.3 EUR. In the past month the price increased by 10.29%.
ChartMill assigns a technical rating of 4 / 10 to 1TMO.MI.
ChartMill assigns a fundamental rating of 4 / 10 to 1TMO.MI. Both the profitability and the financial health of 1TMO.MI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 1TMO.MI reported a non-GAAP Earnings per Share(EPS) of 19.26. The EPS increased by 4.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.02% | ||
| ROA | 6.38% | ||
| ROE | 12.88% | ||
| Debt/Equity | 0.62 |
31 analysts have analysed 1TMO.MI and the average price target is 536.3 EUR. This implies a price decrease of -0.92% is expected in the next year compared to the current price of 541.3.
For the next year, analysts expect an EPS growth of 5.07% and a revenue growth 3.54% for 1TMO.MI
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 47.84 | 20.07B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 47.89 | 20.09B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 55.79 | 19.05B | ||
| SRT.DE | SARTORIUS AG | 43.03 | 14.69B | ||
| QIA.DE | QIAGEN N.V. | 20.81 | 9.56B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 14.7 | 2.15B | ||
| EVT.DE | EVOTEC SE | N/A | 2.09B | ||
| GXI.DE | GERRESHEIMER AG | 6.82 | 869.72M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.81 | 212.22M |
Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. The company is headquartered in Waltham, Massachusetts and currently employs 125,000 full-time employees. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. The company also provides purification and filtration technologies.
THERMO FISHER SCIENTIFIC INC
168 Third Avenue
Waltham MASSACHUSETTS US
Employees: 125000
Phone: 17816221000
Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. The company is headquartered in Waltham, Massachusetts and currently employs 125,000 full-time employees. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. The company also provides purification and filtration technologies.
The current stock price of 1TMO.MI is 541.3 EUR. The price increased by 9.57% in the last trading session.
THERMO FISHER SCIENTIFIC INC (1TMO.MI) has a dividend yield of 0.3%. The yearly dividend amount is currently 1.3.
1TMO.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
1TMO.MI stock is listed on the Euronext Milan exchange.
The Revenue of THERMO FISHER SCIENTIFIC INC (1TMO.MI) is expected to grow by 3.54% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.